April 22, 2009

Pain relievers seem not to prevent Alzheimer's in very old

New research from University of Washington, Veterans Affairs, and Group Health

Seattle—A new  study shows that nonsteroidal anti-inflammatory drugs (NSAIDs), such as the  pain relievers ibuprofen and naproxen, do not prevent Alzheimer's disease or  other forms of dementia. Instead, the risk of developing dementia in the  study's very elderly population (most were over age 83 when they developed  dementia) was 66 percent higher among heavy NSAID users than among people who  used little or no NSAIDs, according to research published online today in Neurology®, the medical journal of the  American Academy of Neurology.

Researchers  identified 2,736 members of Group Health, an integrated health care delivery  system, who did not have dementia when they enrolled in the study at an average  age of 75. The investigators then followed these people for 12 years to see if  they developed Alzheimer's or other forms of dementia. They checked Group Health pharmacy records for NSAIDs (tracking both prescriptions and  over-the-counter use) and also asked participants about their use of NSAIDs.

Of the participants, 351 people had a history of using NSAIDs heavily at the study's start, and another 107 became heavy NSAID users during the follow-up period.  Heavy use was defined as having prescriptions for NSAIDs at least 68 percent of  the time in two years.

During the study, 476 people developed Alzheimer's disease or dementia. The risk of developing dementia among heavy NSAID users was 66 percent higher than among people with little or no NSAID use.

"NSAIDs are useful for relieving pain from conditions including arthritis," said study  author Eric  B. Larson, MD, MPH, executive director of Group Health Center for Health Studies. "Although we hoped to find a protective effect, there was none. Thus, for this age group, there's no basis for taking NSAIDs to prevent Alzheimer's disease. Our study in this quite elderly population showed more risk of dementia with NSAIDs, especially when used heavily."

The study suggests a need to re-interpret earlier findings that suggested NSAIDs can prevent or delay the disease. Why the discrepancy?

"A key difference between this study and most of those done earlier is that our participants were older," said lead study author John C. S. Breitner, MD, MPH, University of Washington professor of psychiatry and head of the Division of Geriatric Psychiatry at the VA Puget Sound Health Care System. "It has been argued for some time that NSAID use delays the onset of Alzheimer's disease. If so, studies of younger NSAID users would show fewer Alzheimer's cases, while groups of older people might show more cases, including those that would have happened earlier if they had not been delayed."

"This is one interpretation of the results, but other explanations are possible," cautioned Breitner. "We must not ignore our main finding: increased risk of dementia in the NSAID users. We need further research to understand that more  clearly."

The U.S. Department of Veterans Affairs, National Institutes of Health,  and Paul B. Beeson Career Development Awards in Aging Research Program  supported the study.

UW Medicine  

Part of the University of Washington, UW Medicine works to improve the health of the public by advancing medical knowledge, providing outstanding primary and specialty care to people  of the region, and preparing tomorrow's physicians, scientists and other health professionals.

About Kaiser Permanente

Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 12.4 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: kp.org/share.


Media contact

For more on Kaiser Permanente Washington Health Research Institute news, please contact:

Amelia Apfel

Amelia.X.Apfel@kp.org

(425) 507-5455
After-hours media line: (206) 287-2055

page-twitter-icon.png @KPWaResearch